The AIDS Healthcare Foundation (AHF) has been battling Gilead over its patents on tenofovir alafenamide fumarate (TAF) since January of 2016. When its federal lawsuit alleging the company manipulated the patent system to enrich itself at the expense of patient safety was dismissed, AHF vowed to appeal the case all the way to the Supreme Court if necessary.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,